Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy

Cellular and Molecular Biology Letters

Volumn 19, Issue 2, 2014, Pages 233-242

  Wang, Ziwen ^a   Huang, Yujung ^a   Zhang, Jiqiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Akt; ATM; Chemotherapy; DNA damage response; Drug resistance; FANCD2; p53; PI3K; Radiotherapy; Ribonucleotide reductase; Target of rapamycin

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASE; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DAMAGE; CELL GROWTH; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA REPLICATION; FANCONI ANEMIA; HUMAN; MOLECULARLY TARGETED THERAPY; REVIEW; STRESS; DNA REPAIR; DRUG EFFECTS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEOTIDE REDUCTASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84903144169     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-014-0191-7     Document Type: Review

References (54)

1. Wullschleger, S., Loewith, R. and Hall, M. N. TOR signaling in growth and metabolism. Cell124 (2006) 471-484.
2. Zoncu, R., Efeyan, A. and Sabatini, D. M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12 (2011) 21-35.
3. Laplante, M. and Sabatini, D. M. mTOR signaling in growth control and disease. Cell149 (2012) 274-293.
4. Cornu, M., Albert, V. and Hall, M. N. mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 23 (2013) 53-62.
5. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004.
6. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science307 (2005) 1098-1101.
7. Hung, C. M., Garcia-Haro, L., Sparks, C. A. and Guertin, D. A. mTORdependent cell survival mechanisms. Cold Spring Harb, Perspect. Biol. 4 (2012) DOI: 10. 1101/cshperspect. a008771.
8. Shaw, R. J. and Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature441 (2006) 424-430.
9. Liu, W., Zhou, Y., Reske, S. N. and Shen, C. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res. 28 (2008) 3613-3620.
10. McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., Mazzarino, M. C., Fagone, P., Nicoletti, F., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Chiarini, F., Evangelisti, C., Cocco, L. and Martelli, A. M. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget3 (2012) 1068-1111.
11. Rodon, J., Dienstmann, R., Serra, V. and Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10 (2013) 143-153.
12. Bjornsti, M. A. and Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer4 (2004) 335-348.
13. Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell100 (2000) 57-70.
14. Luo, J., Solimini, N. L. and Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell136 (2009) 823-837.
15. Dick, F. A. and Rubin, S. M. Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell Biol. 14 (2013) 297-306.
16. Chen, H. Z., Tsai, S. Y. and Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer9 (2009) 785-797.
17. Manning, B. D. and Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell129 (2007) 1261-1274.
18. Heitman, J., Movva, N. R. and Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science253 (1991) 905-909.
19. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M. N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell10 (2002) 457-468.
20. Sarbassov, D. D., Ali, S. M. and Sabatini, D. M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17 (2005) 596-603.
21. Soulard, A. and Hall, M. N. SnapShot: mTOR signaling. Cell129 (2007) 434.
22. Polak, P. and Hall, M. N. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 21 (2009) 209-218.
23. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., Wang, C. Y., He, X., MacDougald, O. A., You, M., Williams, B. O. and Guan, K. L. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell126 (2006) 955-968.
24. Li, Y., Inoki, K., Vacratsis, P. and Guan, K. L. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 278 (2003) 13663-13671.
25. Lee, D. F., Kuo, H. P., Chen, C. T., Hsu, J. M., Chou, C. K., Wei, Y., Sun, H. L., Li, L. Y., Ping, B., Huang, W. C., He, X., Hung, J. Y., Lai, C. C., Ding, Q., Su, J. L., Yang, J. Y., Sahin, A. A., Hortobagyi, G. N., Tsai, F. J., Tsai, C. H. and Hung, M. C. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell130 (2007) 440-455.
26. Astrinidis, A., Senapedis, W., Coleman, T. R. and Henske, E. P. Cell cycleregulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem. 278 (2003) 51372-51379.
27. Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P. and Guan, K. L. Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10 (2008) 935-945.
28. Meric-Bernstam, F. and Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27 (2009) 2278-2287.
29. Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S. and Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8 (2008) 393-412.
30. Moldovan, G. L. and D'Andrea, A. D. How the fanconi anemia pathway guards the genome. Annu. Rev. Genet. 43 (2009) 223-249.
31. Kitao, H. and Takata, M. Fanconi anemia: a disorder defective in the DNA damage response. Int. J. Hematol. 93 (2011) 417-424.
32. Kim, H. and D'Andrea, A. D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 26 (2012) 1393-1408.
33. Kee, Y. and D'Andrea, A. D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 24 (2010) 1680-1694.
34. Knipscheer, P., Raschle, M., Smogorzewska. A., Enoiu, M., Ho, T. V., Scharer, O. D., Elledge, S. J. and Walter, J. C. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science326 (2009) 1698-1701.
35. Joo, W., Xu, G., Persky, N. S., Smogorzewska, A., Rudge, D. G., Buzovetsky, O., Elledge, S. J. and Pavletich, N. P. Structure of the FANCIFANCD2 complex: insights into the Fanconi anemia DNA repair pathway. Science333 (2011) 312-316.
36. Shen, C., Oswald, D., Phelps, D., Cam, H., Pelloski, C. E., Pang, Q. and Houghton, P. J. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks. Cancer Res. 73 (2013) 3393-3401.
37. Kastan, M. B. and Bartek, J. Cell-cycle checkpoints and cancer. Nature432 (2004) 316-323.
38. Guo, F., Li, J., Du, W., Zhang, S., O'Connor, M., Thomas, G., Kozma, S., Zingarelli, B., Pang, Q. and Zheng, Y. mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia27 (2013) 2040-2046.
39. Guo, F., Li, J., Zhang, S., Du, W., Amarachintha, S., Sipple, J., Phelan, J., Grimes, H. L., Zheng, Y. and Pang, Q. mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression. Leukemia28 (2014) 203-206.
40. Huang, M., Zhou, Z. and Elledge, S. J. The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. Cell94 (1998) 595-605.
41. Zhao, X. and Rothstein, R. The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1. Proc. Natl. Acad. Sci. USA99 (2002) 3746-3751.
42. Kolberg, M., Strand, K. R., Graff, P. and Andersson, K. K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta1699 (2004) 1-34.
43. Shen, C., Lancaster, C. S., Shi, B., Guo, H., Thimmaiah, P. and Bjornsti, M. A. TOR signaling is a determinant of cell survival in response to DNA damage. Mol. Cell. Biol. 27 (2007) 7007-7017.
44. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y. and Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature404 (2000) 42-49.
45. D'Angiolella, V., Donato, V., Forrester, F. M., Jeong. Y. T., Pellacani, C., Kudo, Y., Saraf, A., Florens, L., Washburn, M. P. and Pagano, M. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell149 (2012) 1023-1034.
46. Imataka, H., Gradi, A. and Sonenberg, N. A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions in poly(A)-dependent translation. EMBO J. 17 (1998) 7480-7489.
47. Chow, L. M. and Baker, S. J. PTEN function in normal and neoplastic growth. Cancer Lett. 241 (2006) 184-196.
48. Graat, H. C., Carette, J. E., Schagen, F. H., Vassilev, L. T., Gerritsen, W. R., Kaspers, G. J., Wuisman, P. I. and van Beusechem, V. W. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol. Cancer Ther. 6 (2007) 1552-1561.
49. Wang, W. and El-Deiry, W. S. Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 20 (2008) 90-96.
50. Shepard, H. M., Jin, P., Slamon, D. J., Pirot, Z. and Maneval, D. C. Herceptin. Handb. Exp. Pharmacol. 181 (2008) 183-219.
51. Rivera, F., Vega-Villegas, M. E., Lopez-Brea, M. F. and Marquez, R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. 47 (2008) 9-19.
52. Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., James, D., Howard, Z., Dudley, P., Hughes, G., Smith, L., Maguire, S., Hummersone, M., Malagu, K., Menear, K., Jenkins, R., Jacobsen, M., Smith, G. C., Guichard, S. and Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATPcompetitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70 (2010) 288-298.
53. Sangai, T., Akcakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K. A., Miller, T. W., Arteaga, C. L., Mills, G. B., Gonzalez-Angulo, A. M. and Meric-Bernstam, F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin. Cancer Res. 18 (2012) 5816-5828.
54. Vousden, K. H. and Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283.